Clinical Trials Logo

B-Cell Malignancies clinical trials

View clinical trials related to B-Cell Malignancies.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04551963 Completed - B-cell Malignancies Clinical Trials

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Start date: November 15, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.

NCT ID: NCT02343120 Completed - B-cell Malignancies Clinical Trials

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Start date: September 4, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.

NCT ID: NCT02327078 Completed - Lung Cancer Clinical Trials

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Start date: November 26, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT02018861 Completed - B-Cell Malignancies Clinical Trials

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Start date: September 22, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.

NCT ID: NCT01775631 Completed - B-Cell Malignancies Clinical Trials

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Start date: March 2013
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma

NCT ID: NCT00983619 Completed - Cancer Clinical Trials

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Start date: April 16, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).